These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9191316)

  • 1. Large scale comparison of adjuvant effects on immunogenicity and protection in a herpes simplex virus type 1 vaccination model.
    Simms JR; Heath AW; Richardson VJ; Jennings R
    Biochem Soc Trans; 1997 May; 25(2):272S. PubMed ID: 9191316
    [No Abstract]   [Full Text] [Related]  

  • 2. Large-scale comparison of experimental adjuvants with herpes simplex virus vaccine reveals a correlation of protection with IgG2a and IgG2b responses.
    Simms JR; Jennings R; Richardson VJ; Heath AW
    J Med Virol; 2002 Sep; 68(1):82-91. PubMed ID: 12210434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
    Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
    Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines.
    Osorio Y; Cohen J; Ghiasi H
    Invest Ophthalmol Vis Sci; 2004 Feb; 45(2):506-14. PubMed ID: 14744892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response to HSV-1 subunit vaccines--a statistical analysis.
    Simms JR; Heath AW; Richardson VJ; Jennings R
    Dev Biol Stand; 1998; 92():335-40. PubMed ID: 9554289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.
    Sanna PP; De Logu A; Williamson RA; Hom YL; Straus SE; Bloom FE; Burton DR
    Virology; 1996 Jan; 215(1):101-6. PubMed ID: 8553581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
    Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T
    Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccines against herpex simplex virus infections. What's new].
    Hoeller Obrigkeit D; Baron JM
    Hautarzt; 2007 May; 58(5):465-6. PubMed ID: 17450340
    [No Abstract]   [Full Text] [Related]  

  • 15. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H; Hoeller D; Yao F
    J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
    Geiss BJ; Smith TJ; Leib DA; Morrison LA
    J Virol; 2000 Dec; 74(23):11137-44. PubMed ID: 11070010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.
    McLean CS; Ni Challanáin D; Duncan I; Boursnell ME; Jennings R; Inglis SC
    Vaccine; 1996 Jul; 14(10):987-92. PubMed ID: 8873393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
    Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
    Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A killed commercial vaccine against herpes simplex viruses 1 and 2 as an immunocorrective agent in chronic herpetic infection].
    Barinskiĭ IF; Kasparov AA; Lazarenko AA; Alimbarova LM; Davydova AA; Belkina IV; Platonova AL
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):98-102. PubMed ID: 10876868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.